Editas Medicine Inc (EDIT) Stock Analysis
Verdict: AVOID
With a ~10-month cash runway ($146.6M cash vs -$165.8M annual FCF) and severe dilution history, EDIT faces binary clinical execution risk.
Investment score: 33/100
Analysis as of
Is Editas Medicine Inc stock worth reviewing? The TradeMates thesis
The TradeMates model views Editas Medicine as a speculative clinical-stage biotech constrained by an acute cash runway (~10.6 months based on 2025 FCF burn of -$165.85M) and long-term share dilution.
7-factor investment score
- Valuation: 25/100 (weight 20%)
- Financial Health: 15/100 (weight 15%)
- Technical Momentum: 35/100 (weight 15%)
- Earnings Quality: 55/100 (weight 15%)
- Insider Sentiment: 30/100 (weight 10%)
- Analyst Consensus: 60/100 (weight 10%)
- Risk-Adjusted Return: 20/100 (weight 15%)
Editas Medicine Inc opportunities and risks
What speaks for EDIT
- Initiation of EDIT-401 First-in-Human Clinical Trial
What speaks against EDIT
- Severe Cash Runway Constraint and Dilution Risk
Peers and competitors
- BBOT
- 2257.HK
- BNTC
- CCCC
- RZLT
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| EDIT | n/a | 8.7x | n/a | 56.9% | -157.3% | -29.6% |
| BBOT | n/a | 0.0x | n/a | 0.0% | 0.0% | -43.8% |
| BNTC | n/a | 755.1x | n/a | -14.2% | -8792.1% | -4.9% |
| CCCC | n/a | 10.7x | n/a | 94.9% | -289.4% | -22.7% |
| RZLT | n/a | 0.0x | n/a | 0.0% | 0.0% | -18.3% |
| Peer median | n/a | 5.4x | n/a | 0.0% | -144.7% | -20.5% |
Frequently asked questions about Editas Medicine Inc (EDIT)
Is EDIT stock a good investment?
The TradeMates model rates Editas Medicine Inc as AVOID with an investment score of 33/100. The TradeMates model views Editas Medicine as a speculative clinical-stage biotech constrained by an acute cash runway (~10.6 months based on 2025 FCF burn of -$165.85M) and long-term share dilution. This is algorithmic model output, not personal investment advice.
Is EDIT stock a buy?
The TradeMates model verdict for EDIT is AVOID with an investment score of 33/100. Treat this as a model signal to review, not a personal buy recommendation.